| 1. |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 4.2017). (2017-11-09)[2018-02-02]. https://www.nccn.org/professionals/physician.
|
| 2. |
Pujade-Lauraine E, Ledermann JA, Selle FA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol, 2017, 18(9): 1274-1284.
|
| 3. |
Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol, 2015, 16(8): 928-936.
|
| 4. |
Duska LR, Java JJ, Cohn DE, et al. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236) Gynecol Oncol, 2015, 139(2): 221-227.
|
| 5. |
Kim JW, Mahner S, Wu LY, et al. Pazopanib maintenance therapy in East Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian study. Int J Gynecol Cancer, 2018, 28(1): 2-10.
|
| 6. |
Committee on Practice Bulletins-Gynecology, Committee on Genetics, Society of Gynecologic Oncology. Practice bulletin no 182: hereditary breast and ovarian cancer syndrome. Obstet Gynecol, 2017, 130(3): e110-e126.
|
| 7. |
Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase Ⅲ GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer, 2012, 107(4): 588-591.
|
| 8. |
Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, 2003, 361(9375): 2099-2106.
|
| 9. |
Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol, 2006, 24(29): 4699-4707.
|
